Richard Daneman
Auto-generated profile, based on publicly available information

Richard Daneman

University of California, San Diego

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2015 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
RDRichard Daneman
Richard Daneman
APAlexandre Prat
Alexandre Prat
Blood vessels are critical to deliver oxygen and nutrients to all of the tissues and organs throughout the body. The blood vessels that vascularize the central nervous system (CNS) possess unique properties, termed the blood–brain barrier, which allow these vessels to tightly regulate the movement of ions, molecules, and cells between the blood and the brain. This precise control of CNS homeostasis allows for proper neuronal function and also protects the neural tissue from toxins and pathogens, and alterations of these barrier properties are an important component of pathology and progression of different neurological diseases. The physiological barrier is coordinated by a series of physical, transport, and metabolic properties possessed by the endothelial cells (ECs) that form the walls of the blood vessels, and these properties are regulated by interactions with different vascular, immune, and neural cells. Understanding how these different cell populations interact to regulate the barrier properties is essential for understanding how the brain functions during health and disease.

25 March 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CPCaterina P. Profaci
Caterina P. Profaci
RMRoeben N. Munji
Roeben N. Munji
RPRobert S. Pulido
Robert S. Pulido
RDRichard Daneman
Richard Daneman
The blood vessels vascularizing the central nervous system exhibit a series of distinct properties that tightly control the movement of ions, molecules, and cells between the blood and the parenchyma. This “blood–brain barrier” is initiated during angiogenesis via signals from the surrounding neural environment, and its integrity remains vital for homeostasis and neural protection throughout life. Blood–brain barrier dysfunction contributes to pathology in a range of neurological conditions including multiple sclerosis, stroke, and epilepsy, and has also been implicated in neurodegenerative diseases such as Alzheimer’s disease. This review will discuss current knowledge and key unanswered questions regarding the blood–brain barrier in health and disease.

14 October 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RMRoeben Nocon Munji
Roeben Nocon Munji
ASAllison Luen Soung
Allison Luen Soung
GWGeoffrey Aaron Weiner
Geoffrey Aaron Weiner
FSFabien Sohet
Fabien Sohet
BSBridgette Deanne Semple
Bridgette Deanne Semple
RDRichard Daneman
Richard Daneman

20 April 2022 in Nature
Verified
Journal Article
Closed access
PDF file
TMTakahiro Masuda
Takahiro Masuda
LALukas Amann
Lukas Amann
GMGianni Monaco
Gianni Monaco
RSRoman Sankowski
Roman Sankowski
OSOri Staszewski
Ori Staszewski
MPMarco Prinz
Marco Prinz

14 November 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QHQin Huang
Qin Huang
KCKen Y Chan
Ken Y Chan
ITIsabelle G Tobey
Isabelle G Tobey
YCYujia Alina Chan
Yujia Alina Chan
TPTim Poterba
Tim Poterba
BDBenjamin E Deverman
Benjamin E Deverman
The engineered AAV-PHP.B family of adeno-associated virus efficiently delivers genes throughout the mouse central nervous system. To guide their application across disease models, and to inspire the development of translational gene therapy vectors for targeting neurological diseases in humans, we sought to elucidate the host factors responsible for the CNS tropism of the AAV-PHP.B vectors. Leveraging CNS tropism differences across 13 mouse strains, we systematically determined a set of genetic variants that segregate with the permissivity phenotype, and rapidly identified LY6A as an essential receptor for the AAV-PHP.B vectors. Interfering with LY6A by CRISPR/Cas9-mediated Ly6a disruption or with blocking antibodies reduced transduction of mouse brain endothelial cells by AAV-PHP.eB, while ectopic expression of Ly6a increased AAV-PHP.eB transduction of HEK293T and CHO cells by 30-fold or more. Importantly, we demonstrate that this newly discovered mode of AAV binding and transduction can occur independently of other known AAV receptors. These findings illuminate the previously reported species- and strain-specific tropism characteristics of the AAV-PHP.B vectors and inform ongoing efforts to develop next-generation AAV vehicles for human CNS gene therapy.

1 November 2015 in Mechanisms of Development
Verified
Journal Article
Closed access
MBMarie Blanchette
Marie Blanchette
RDRichard Daneman
Richard Daneman